Archive Site Provided for Historical Purposes
Sponsored by the U.S. Department of Energy Human Genome Program
In this issue...
Available in PDF
In the News
Web, Publications, Resources
Meeting Calendars & Acronyms
Brookhaven National Laboratory, New York
One of the world's leading laboratories for the design, synthesis, and application of radiopharmaceuticals for such priorities as substance abuse, aging and degenerative diseases, and the biology of tumors.
Lawrence Berkeley National Laboratory, California
Specialized instrument development to improve detection of prostate, breast, and other cancers for such priorities as SPECT imaging for brain studies of mental illness. New radiotracers to study aging, heart disease, and cancer.
Oak Ridge National Laboratory, Tennessee
Genesis of BER when ORNL made available a vast selection of radionuclides for nuclear medicine research. Studies of new radiopharmaceuticals' potential for diagnostic and therapeutic applications in cancer and coronary artery disease.
Memorial Sloan-Kettering Cancer Center, New York
Pioneering work in the use of "monoclonal antibodies" to treat cancer. Novel ways to produce a variety of radionuclides to treat lymphoma, leukemia, and prostate cancer.
University of California, Los Angeles
New ways to image the biology and genetics of several diseases, including cancer, diabetes, heart disease, Alzheimer's disease, and Parkinson's disease. Pioneers in PET and microPET, which allows scientists to watch cells at work in the living person or mouse.
Washington University, St. Louis, Missouri
Innovative use of radionuclides in medicine. Important contributions to PET. Development of new organic carrier molecules and a new class of PET radio-pharmaceuticals based on metal radionuclides and first hormone receptor agents.
University of Michigan, Ann Arbor
Research in the chemical design and synthesis of radiopharmaceuticals and their implementation in PET and SPECT brain-chemistry studies. Development of computer science for nuclear medicine imaging systems. Insight into several neurological disorders that affect movement, memory, aging, and dementia.
The electronic form of the newsletter may be cited in the following style:
Human Genome Program, U.S. Department of Energy, Human Genome News (v11n3-4).
The Human Genome Project (HGP) was an international 13-year effort, 1990 to 2003. Primary goals were to discover the complete set of human genes and make them accessible for further biological study, and determine the complete sequence of DNA bases in the human genome. See Timeline for more HGP history.